Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Kinarti is a privately owned investment company founded in Israel, dedicated to early-stage startup investments in technological, biomedical, and biotech initiatives. The firm emphasizes a dual approach of providing both financial backing and intellectual support to its portfolio companies. Kinarti's team comprises seasoned experts in science and engineering, who collaborate closely with startups to navigate complex challenges and ensure they have the necessary resources for success.
As of now, Kinarti operates globally, leveraging its connections with leading academic institutions such as Hebrew University, Technion, and Weizmann Institute. The firm has established a reputation for its hands-on approach, which includes not only capital investment but also comprehensive business strategy assistance. This includes guidance on structure, regulation, taxation, due diligence, financial planning, and marketing.
Kinarti's commitment to empowering entrepreneurs is reflected in its investment thesis, which focuses on sectors that are at the forefront of innovation, such as drug development, biotechnology, medical devices, quantum physics, quantum computing, semiconducting technologies, and aeronautics. The firm continues to evolve, seeking opportunities to partner with innovative startups that align with its strategic vision.
Kinarti invests primarily in early-stage startups across the technology, biomedical, and biotech sectors. The firm employs a flexible investment model that emphasizes direct and smart investments, coupled with a hands-on approach to assist entrepreneurs in overcoming capital raising challenges. Their investment strategy is designed to provide both financial resources and intellectual support, ensuring that startups can effectively navigate the complexities of their respective industries.
The sectors of focus for Kinarti include drug development, biotechnology, medical devices, quantum physics, quantum computing, semiconducting technologies, and aeronautics. This diverse range allows the firm to tap into various innovative fields, enhancing its portfolio's potential for growth. Kinarti's geographic focus is global, with a primary emphasis on Israel, leveraging its strong ties to local academic and industry networks.
Kinarti's investment model is built on a three-pillar support system: capital investment, intellectual advisory from top scientists and engineers, and comprehensive business strategy assistance. This model ensures that startups receive not only the necessary funding but also the strategic guidance needed to thrive in competitive markets.
Dr. Oron Yacoby Zeevi - Chief Scientific Officer. Dr. Zeevi has over 20 years of experience in the biopharmaceutical industry, previously serving as VP of R&D at Neuroderm, which was sold to Mitsubishi Tanabe Pharma for $1.1 billion. He holds over 50 patents and brings extensive expertise in drug development and biotechnology.
Prof. Amir Yacoby - Professor of Physics at Harvard University. Prof. Yacoby is a member of the National Academy of Sciences and specializes in quantum computing and materials science, contributing significant academic and practical insights to Kinarti's investment strategy.
Roi Zeevi - Entrepreneur and investor. Roi founded the Solan investment platform and has a decade of experience as an Israeli Air Force officer, bringing a unique perspective to the firm's investment approach.
Hilla Kochavi - Marketing Specialist. Hilla has 12 years of experience in high-tech and biotech startups, focusing on branding and positioning, which is crucial for the success of portfolio companies.
To pitch Kinarti, founders should use the contact form available on their website. A detailed pitch deck is essential, including information about the business model, market opportunity, and team background. Kinarti values clarity and innovation in pitches.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, as they can enhance the likelihood of a favorable review.
What are Kinarti's investment criteria?
Kinarti focuses on early-stage startups in the technology, biomedical, and biotech sectors. They look for innovative companies that can benefit from both capital investment and intellectual support.
How can startups apply or pitch to Kinarti?
Startups interested in pitching to Kinarti should reach out through their contact form on the website. A detailed pitch deck outlining the business model, market opportunity, and team background is recommended.
What makes Kinarti different from other investors?
Kinarti distinguishes itself through its three-pillar support model, which combines capital investment with intellectual advisory and business strategy assistance. This hands-on approach is designed to help startups navigate the complexities of their industries.
What is Kinarti's geographic scope?
While Kinarti is based in Israel, they have a global investment focus, leveraging connections with academic and industry networks worldwide.
What is the typical check size Kinarti invests?
Specific check sizes have not been disclosed, but Kinarti invests in early-stage rounds, including pre-seed, seed, seed-plus, and Series A funding.
What kind of post-investment involvement does Kinarti have?
Kinarti maintains a hands-on approach post-investment, providing ongoing support in business strategy, regulatory issues, and market positioning to help startups succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.